An interventional study of active product and reference product in Diabetes Mellitus, Type 2, Obesity and Overweight, sponsored by Stoffwechselzentrum Rhein - Pfalz. Completed at 1 site in Germany. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-10-22.
Sponsored by Stoffwechselzentrum Rhein - Pfalz · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany — 46 open to participants now, 67 under way, 23 of them phase 3. Diabetes Mellitus, Type 2 · Germany.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, this one is the 580th largest by enrollment of the 688 interventional ones that give a count, is one of 26 that started in 2019, is one of 87 with no phase, and was the 580th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →46 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany are open now. Recruiting first, the newest first:
German Institute of Human Nutrition · Sites in Germany
Ages 40–75 · Healthy volunteers
Novo Nordisk A/S · Sites in Germany
Ages 25–69 · Healthy volunteers
Eli Lilly and Company · Sites in Germany, United States, Argentina and 8 more countries
Ages 18+
German Institute of Human Nutrition · Sites in Germany
Ages 40–75 · Healthy volunteers
Ascletis Pharma (China) Co., Limited · Sites in Germany, United States, Czechia and 3 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
756 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 104 · Phase 3 285 · Phase 4 79
First in 1998; this study’s year is marked. 26 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 218 across the 688 interventional studies, 1,552 across the 66 observational. Of the 655 that completed or were terminated, 263 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
597 of 756 have an industry lead sponsor. The 10 most frequent:
Stoffwechselzentrum Rhein - Pfalz is the lead sponsor of 3 studies on the registry; none are open to participants now.
Stoffwechselzentrum Rhein - Pfalz has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
18 of the studies in Diabetes Mellitus, Type 2 with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
Add all 18 to your calendar (.ics) → With an account.
Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effects of an ad libitum addition of a high fiber product to the regular diet of type 2 diabetes patients on body weight and blood sugar control. In the first 6 weeks half of the participants will receive the high fiber test product and half a reference product without fiber. After the first 6 weeks both groups will be switched to the high fiber product.
It has previously been shown that an increase in the consumption of fiber improves glucose control in type 2 diabetes. In addition, previous pilot studies have shown that a diet solely based on oat flakes can improve insulin sensitivity and glucose control in poorly controlled type 2 diabetes. Recent clinical data indicates, that early hyperglycemia can be normalized by a diet high in fiber. In this controlled pilot study, a food containing liquid oat bran high in fiber will be studied in type 2 diabetes patients with inadequate glucose control that are treated with oral medication or with additional once-daily insulin only against a reference product. 30 patients will be treated with the oat bran product or reference product over a period of 6 weeks in a double blinded approach, hereafter all participants will be switched to the oat bran product. The primary endpoint will be fasting glucose after 6 weeks. Secondary endpoints will be long-term glucose control as measured by HbA1c, self-documented glucose as well as the body weight and body mass index.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
Other: active product
Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
Other: active product · Other: reference product
Once daily consumption over the period of the study
Also known as: LOB, Liquid Oat Bran, High fiber product
Once daily consumption over the period of the study
Also known as: placebo food product
Fasting glucose
Change in the concentratino of fasting venous glucose of daily LOB consumption in mg/dl as compared to the change in fasting glucose for the placebo group at 6 weeks.
Time frame: 6 weeks
Fasting glucose
Change in the concentratino of fasting venous glucose of daily LOB consumption in mg/dl as compared to the change in fasting glucose for the placebo group at 12 weeks.
Time frame: 12 weeks
HBA1c
long-term glucose control as measured by the concentratino of HbA1c concentration in %
Time frame: 6 weeks
HBA1c
long-term glucose control as measured by the concentratino of HbA1c concentration in %
Time frame: 12 weeks
Self-documented glucose
Self-monitored glucose levels extracted from glucometers as a mean of the previous two weeks before study visits in mg/dl
Time frame: 6 weeks
Self-documented glucose
Self-monitored glucose levels extracted from glucometers as a mean of the previous two weeks before study visits in mg/dl
Time frame: 12 weeks
Weight
Chenge in body Weight in kg
Time frame: 6 weeks
Weight
Chenge in body Weight in kg
Time frame: 12 weeks
BMI
Body Mass Index
Time frame: 6 weeks
BMI
Body Mass Index
Time frame: 12 weeks
Lipid metabolism: Serum triglycerides
Markers of lipid metabolism at 6 weeks: triglycerides (mg/dl)
Time frame: 6 weeks
Lipid metabolism: Serum triglycerides
Markers of lipid metabolism at 12 weeks: triglycerides (mg/dl)
Time frame: 12 weeks
Lipid metabolism: apolipoprotein A (mg/dl)
Markers of lipid metabolism at 6 weeks: apolipoprotein A (mg/dl)
Time frame: 6 weeks
Lipid metabolism: apolipoprotein A (mg/dl)
Markers of lipid metabolism at 12 weeks: apolipoprotein A (mg/dl)
Time frame: 12 weeks
Lipid metabolism: Apolipoprotein B mg/dl
Markers of lipid metabolism at 6 weeks: Apolipoprotein B mg/dl
Time frame: 6 weeks
Lipid metabolism: Apolipoprotein B mg/dl
Markers of lipid metabolism at 12 weeks: Apolipoprotein B mg/dl
Time frame: 12 weeks
Lipid metabolism: Apolipoprotein B / Apolipoprotein A ratio
Metabolism at 6 weeks: Apolipoprotein B mg/dl / Apolipoprotein A mg/dl ratio
Time frame: 6 weeks
Lipid metabolism: Apolipoprotein B / Apolipoprotein A ratio
Markers of lipid metabolism at 12 weeks: Apolipoprotein B mg/dl / Apolipoprotein A mg/dl ratio
Time frame: 12 weeks
Lipid metabolism: HDL-cholesterol
Markers of lipid metabolism at 6 weeks: HDL-cholesterol mg/dl
Time frame: 6 weeks
Lipid metabolism: HDL-cholesterol
Markers of lipid metabolism at 12 weeks: HDL-cholesterol mg/dl
Time frame: 12 weeks
Lipid metabolism: LDL- cholesterol mg/dl
Markers of lipid metabolism at 6 weeks: LDL- cholesterol mg/dl
Time frame: 6 weeks
Lipid metabolism: LDL- cholesterol mg/dl
Markers of lipid metabolism at 12 weeks: LDL- cholesterol mg/dl
Time frame: 12 weeks
Microbiome
Microbiome in faeces samples at 6 weeks
Time frame: 6 weeks
Microbiome
Microbiome in faeces samples at 12 weeks
Time frame: 12 weeks
Inflammation: Il-6
Markers of inflammation at 6 weeks IL-6 in ng/ml
Time frame: 6 weeks
Inflammation: hsCRP
Markers of inflammation at 6 weeks hsCRP mg/l
Time frame: 6 weeks
Inflammation: Il-6
Markers of inflammation at 12 weeks IL-6 in ng/ml
Time frame: 12 weeks
Inflammation: hsCRP
Markers of inflammation at 12 weeks hsCRP mg/l
Time frame: 12 weeks
Systolic lood pressure
Systolic blood pressure left arm 6 weeks in mm/Hg
Time frame: 6 weeks
Diastolic blood pressure
Diastolic blood pressure left arm 6 weeks in mm/Hg
Time frame: 6 weeks
Systolic blood pressure
Systolic blood pressure left arm 12 weeks in mm/Hg
Time frame: 12 weeks
Diastolic blood pressure
Diastolic blood pressure left arm 12 weeks in mm/Hg
Time frame: 12 weeks
Waist circumference
Waist circumference at 6 weeks in cm
Time frame: 6 weeks
Waist circumference
Waist circumference at 12 weeks in cm
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2019 to primary completion in Apr 2020, 13 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 13 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stoffwechselzentrum Rhein - Pfalz